Literature DB >> 28314315

PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.

Akiyuki Wakita1, Satoru Motoyama2, Hiroshi Nanjo3, Yusuke Sato2, Kei Yoshino2, Tomohiko Sasaki2, Yuta Kawakita2, Jiajia Liu2, Kazuhiro Imai2, Hajime Saito2, Yoshihiro Minamiya2.   

Abstract

BACKGROUND/AIM: Programmed death-1 ligand 1 (PD-L1) induces apoptosis of tumor-reactive T-cells, that enables tumors to evade immune defense and thus furthers their growth. Our aim was to determine whether PD-L1 expression status correlates with prognosis in patients with advanced thoracic esophageal squamous cell carcinoma. PATIENTS AND METHODS: The PD-L1 expression status of 177 patients treated with esophagectomy without preoperative therapy was evaluated immunohistochemically using tissue microarray. We then statistically analyzed the relationships between PD-L1 expression status and clinicopathological features and survival.
RESULTS: In patients undergoing surgery alone, PD-L1 expression was significantly positivity associated with a better prognosis. By contrast, there were no significant correlations between PD-L1 expression and clinicopathological features or outcomes in patients treated with surgery plus postoperative adjuvant chemotherapy.
CONCLUSION: PD-L1 positivity in advanced thoracic esophageal squamous cell carcinoma may be predictive of a positive prognosis in patients treated without adjuvant chemotherapy. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  PD-L1; esophageal cancer; immunochemistry; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28314315     DOI: 10.21873/anticanres.11467

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.

Authors:  Dagmar Kollmann; Desislava Ignatova; Julia Jedamzik; Yun-Tsan Chang; Gerd Jomrich; Andreas Baierl; Dmitry Kazakov; Michal Michal; Lars E French; Wolfram Hoetzenecker; Tobias Schatton; Reza Asari; Matthias Preusser; Michael Gnant; Emmanuella Guenova; Sebastian F Schoppmann
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

2.  Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.

Authors:  Qiang Wen; Zhe Yang; Jian Zhu; Qingtao Qiu; Honghai Dai; Alei Feng; Ligang Xing
Journal:  Onco Targets Ther       Date:  2020-11-20       Impact factor: 4.147

3.  Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.

Authors:  Youwen Zhu; Kun Liu; Dong Ding; Yangying Zhou; Libo Peng
Journal:  Adv Ther       Date:  2022-04-08       Impact factor: 4.070

4.  Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.

Authors:  Ramy R Saleh; Jordan L Scott; Nicholas Meti; Danielle Perlon; Rouhi Fazelzad; Alberto Ocana; Eitan Amir
Journal:  Mol Diagn Ther       Date:  2022-02-01       Impact factor: 4.074

5.  CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.

Authors:  Cao Gao; Yan-Jie Xu; Lei Qi; Ya-Fei Bao; Lei Zhang; Liang Zheng
Journal:  Cell Biol Toxicol       Date:  2021-05-20       Impact factor: 6.819

6.  PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.

Authors:  Matteo Fassan; Francesco Cavallin; Vincenza Guzzardo; Andromachi Kotsafti; Melania Scarpa; Matteo Cagol; Vanna Chiarion-Sileni; Luca Maria Saadeh; Rita Alfieri; Ignazio Castagliuolo; Massimo Rugge; Carlo Castoro; Marco Scarpa
Journal:  Cancer Med       Date:  2019-08-20       Impact factor: 4.452

Review 7.  Role of the tumor immune microenvironment in tumor immunotherapy.

Authors:  Changsheng Zhou; Qianqian Liu; Yi Xiang; Xin Gou; Wengang Li
Journal:  Oncol Lett       Date:  2021-12-20       Impact factor: 2.967

8.  Prognostic factor analysis for patient outcome of PD-L1 expression in thoracic oesophageal squamous cell carcinoma.

Authors:  Bo Wu; Jianhua Gao; Muyuan Ma; Yuanyuan Wu; Xiaofeng Ye
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-04

9.  PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.

Authors:  Qiao Wang; Fan Feng; Fei Wang; Zhen Liu; Shushang Liu; Guanghui Xu; Gaozan Zheng; Man Guo; Xiao Lian; Hongwei Zhang
Journal:  J Cancer       Date:  2018-06-05       Impact factor: 4.207

Review 10.  Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature.

Authors:  Weiwei Yu; Yanmei Guo
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.